IMR Press / FBL / Volume 23 / Issue 12 / DOI: 10.2741/4701

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

High-density lipoprotein carbamylation and dysfunction in vascular disease

Show Less
1 Department of Anesthesiology, SUNY Downstate Medical Center, Brooklyn, NY, United States
2 Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, United States
Front. Biosci. (Landmark Ed) 2018, 23(12), 2227–2234; https://doi.org/10.2741/4701
Published: 1 June 2018
Abstract

High-density lipoprotein (HDL) is cardioprotective because of its anti-atherogenic properties. Nevertheless, our goal to optimize HDL cholesterol (HDL-C) levels have had little effects on the atherothrombotic burden and suggests a closer look be taken at HDL function and dysfunction. HDL is a group of complex macromolecules composed of a lipid- and proteome that work in synergy to execute its anti-inflammatory, anti-atherogenic, and anti-thrombotic effects. However, throughout its life-span in circulation, HDL undergoes significant modification. Carbamylation, a non-enzymatic and irreversible post-translational modification of protein, is one effector of HDL which has growing evidence that it plays a crucial role in the development and progression of atherosclerotic cardiovascular disease (ASCVD), particularly in chronic kidney disease (CKD). We summarize HDL’s function, susceptibility to modification, and discuss HDL carbamylation and its effect in cardiovascular disease.

Keywords
HDL
Carbamylation
Lipoprotein dysfunction
Vascular disease
Review
Share
Back to top